BioCentury
ARTICLE | Politics, Policy & Law

PDUFA VII to feature $4M fee, focus on cell, gene therapies

Funding increases for CBER as FDA expects onslaught of applications for new modality therapies

By Steve Usdin, Washington Editor
March 12, 2021 9:32 PM UTC

FDA and biopharma industry representatives have agreed on most elements of the next Prescription Drug User Fee Act deal, including an increase in the application fee to about $4 million by 2027 from ...



Access this Article

BCIQ Company Profiles

U.S. Food and Drug Administration (FDA)